Dachaigh › Leukemia biphenotypic geur › Massachusetts
Sgrùdaidhean clionaigeach Leukemia biphenotypic geur ann an Massachusetts
Tha 5 sgrùdaidhean airson Leukemia biphenotypic geur a’ lorg phàirtichean aig làraichean ann an Massachusetts.
Bailtean ann an Massachusetts
Teacsa sgrùdaidh oifigeil (Beurla)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
A’ fastadhÌre 2
365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- agus 1 a bharrachd
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1/2
Suas gu aois 22 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT04726241Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1
Aoisean 1 gu 40 · Gach gnè · Air ùrachadh 12 Màrt 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
A’ fastadhÌre 1
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 6 Dùbh 2024 · NCT05476770Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.